NO974766D0 - Fremgangsmåte for behandling av dysfunksjon - Google Patents
Fremgangsmåte for behandling av dysfunksjonInfo
- Publication number
- NO974766D0 NO974766D0 NO974766A NO974766A NO974766D0 NO 974766 D0 NO974766 D0 NO 974766D0 NO 974766 A NO974766 A NO 974766A NO 974766 A NO974766 A NO 974766A NO 974766 D0 NO974766 D0 NO 974766D0
- Authority
- NO
- Norway
- Prior art keywords
- dysfunction
- procedure
- treatment
- methyl
- benzodiazepine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pretreatment Of Seeds And Plants (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Percussion Or Vibration Massage (AREA)
- Processing Of Meat And Fish (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Light Receiving Elements (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002219902A CA2219902A1 (en) | 1995-05-30 | 1995-05-30 | Use of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine for treating cognitive dysfunction |
NO19974766A NO318553B1 (no) | 1995-05-30 | 1997-10-15 | Anvendelse av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno[2,3-b][1,5]benzodiazepin for behandling av en kognitiv dysfunksjon. |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002219902A CA2219902A1 (en) | 1995-05-30 | 1995-05-30 | Use of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine for treating cognitive dysfunction |
PCT/US1995/006859 WO1996038151A1 (en) | 1995-05-30 | 1995-05-30 | Method for treating cognitive dysfunction |
NO19974766A NO318553B1 (no) | 1995-05-30 | 1997-10-15 | Anvendelse av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno[2,3-b][1,5]benzodiazepin for behandling av en kognitiv dysfunksjon. |
Publications (3)
Publication Number | Publication Date |
---|---|
NO974766D0 true NO974766D0 (no) | 1997-10-15 |
NO974766L NO974766L (no) | 1997-12-09 |
NO318553B1 NO318553B1 (no) | 2005-04-11 |
Family
ID=25679786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19974766A NO318553B1 (no) | 1995-05-30 | 1997-10-15 | Anvendelse av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno[2,3-b][1,5]benzodiazepin for behandling av en kognitiv dysfunksjon. |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0828494B1 (no) |
JP (1) | JPH11506096A (no) |
AT (1) | ATE220550T1 (no) |
AU (1) | AU707858B2 (no) |
CZ (1) | CZ292565B6 (no) |
DE (1) | DE69527442T2 (no) |
DK (1) | DK0828494T3 (no) |
ES (1) | ES2180643T3 (no) |
FI (1) | FI973987A (no) |
HK (1) | HK1009393A1 (no) |
HU (1) | HUT77907A (no) |
MX (1) | MX9707936A (no) |
NO (1) | NO318553B1 (no) |
NZ (1) | NZ288037A (no) |
PL (1) | PL189714B1 (no) |
PT (1) | PT828494E (no) |
WO (1) | WO1996038151A1 (no) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3274579B2 (ja) * | 1995-01-12 | 2002-04-15 | 住友製薬株式会社 | 脳血管障害に伴う精神症候治療剤 |
UA57727C2 (uk) * | 1996-03-11 | 2003-07-15 | Елі Ліллі Енд Компані | Спосіб лікування надмірної агресивності |
PL196814B1 (pl) | 2002-05-17 | 2008-02-29 | Inst Farmaceutyczny | Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty |
AR047459A1 (es) | 2004-01-27 | 2006-01-18 | Synthon Bv | Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina) |
WO2006073886A1 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Olanzapine pamoate dihydrate |
PL381564A1 (pl) | 2007-01-22 | 2008-08-04 | Koźluk Tomasz Nobilus Ent | Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270464A (en) * | 1989-03-14 | 1993-12-14 | Janssen Pharmaceutica N.V. | Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones |
GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
-
1995
- 1995-05-30 PL PL95323785A patent/PL189714B1/pl not_active IP Right Cessation
- 1995-05-30 AU AU26936/95A patent/AU707858B2/en not_active Ceased
- 1995-05-30 CZ CZ19973243A patent/CZ292565B6/cs not_active IP Right Cessation
- 1995-05-30 DK DK95922148T patent/DK0828494T3/da active
- 1995-05-30 DE DE69527442T patent/DE69527442T2/de not_active Expired - Fee Related
- 1995-05-30 EP EP95922148A patent/EP0828494B1/en not_active Expired - Lifetime
- 1995-05-30 JP JP8536420A patent/JPH11506096A/ja active Pending
- 1995-05-30 ES ES95922148T patent/ES2180643T3/es not_active Expired - Lifetime
- 1995-05-30 HU HU9801173A patent/HUT77907A/hu not_active Application Discontinuation
- 1995-05-30 WO PCT/US1995/006859 patent/WO1996038151A1/en active IP Right Grant
- 1995-05-30 MX MX9707936A patent/MX9707936A/es not_active IP Right Cessation
- 1995-05-30 AT AT95922148T patent/ATE220550T1/de not_active IP Right Cessation
- 1995-05-30 PT PT95922148T patent/PT828494E/pt unknown
- 1995-05-30 NZ NZ288037A patent/NZ288037A/en unknown
-
1997
- 1997-10-15 NO NO19974766A patent/NO318553B1/no unknown
- 1997-10-17 FI FI973987A patent/FI973987A/fi not_active IP Right Cessation
-
1998
- 1998-08-26 HK HK98110242A patent/HK1009393A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0828494A4 (en) | 1999-11-24 |
DK0828494T3 (da) | 2002-09-02 |
DE69527442T2 (de) | 2003-02-20 |
HK1009393A1 (en) | 1999-06-04 |
AU707858B2 (en) | 1999-07-22 |
ATE220550T1 (de) | 2002-08-15 |
PT828494E (pt) | 2002-10-31 |
CZ324397A3 (cs) | 1998-08-12 |
CZ292565B6 (cs) | 2003-10-15 |
EP0828494B1 (en) | 2002-07-17 |
HUT77907A (hu) | 1998-10-28 |
PL189714B1 (pl) | 2005-09-30 |
MX9707936A (es) | 1997-12-31 |
PL323785A1 (en) | 1998-04-27 |
FI973987A0 (fi) | 1997-10-17 |
NO318553B1 (no) | 2005-04-11 |
WO1996038151A1 (en) | 1996-12-05 |
JPH11506096A (ja) | 1999-06-02 |
NO974766L (no) | 1997-12-09 |
AU2693695A (en) | 1996-12-18 |
DE69527442D1 (de) | 2002-08-22 |
NZ288037A (en) | 1999-09-29 |
FI973987A (fi) | 1997-10-17 |
ES2180643T3 (es) | 2003-02-16 |
EP0828494A1 (en) | 1998-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY114701A (en) | Process and crystal forms of 2-methyl-thieno- benzodiazepine | |
IL113912A (en) | Use of 2-methyl-10-(4-methyl-1- piperazinyl)-4h-thieno-[2,3-b] [1,5] benzodiazepine for the treatment of functional bowel disorders | |
NO178766C (no) | Analogifremgangsmåte for fremstilling av benzodiazepin og mellomprodukter derav | |
NO961483D0 (no) | Fremgangsmåte for behandling av oljeholdig formasjon | |
ZA963098B (en) | Method for treating dyskinesias. | |
NZ510208A (en) | Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine) pamoate salt | |
EP1181935A3 (en) | Agent for treating mental disorders associated with cerebrovascular disorders | |
NO974766D0 (no) | Fremgangsmåte for behandling av dysfunksjon | |
ZA971566B (en) | Method of treating leather with pmphoteric polymers. | |
NO982911L (no) | FremgangsmÕte for behandling av depresjon | |
TW429149B (en) | Pharmaceutical composition for treating conditions resulting from the cessation and withdrawal from the use of nicotine | |
NZ332037A (en) | Olanzapine for treating migraine pain | |
EP0911028A3 (en) | Method for treating sexual dysfunction | |
DK0831835T3 (da) | Behandling af anorexia | |
IL128028A0 (en) | Treatment of psychotic disorders | |
NZ324615A (en) | Method for treating autism using olanzapine | |
AU2874497A (en) | Balanites aegyptiaca method of treatment | |
HUP9902882A2 (hu) | Olanzapin alkalmazása álmatlanság kezelésére szolgáló gyógyszerkészítmények előállítására | |
NZ331846A (en) | Method for preparing a medicament using olanzapine for treating insomnia | |
ZA963472B (en) | Method of treatment. | |
ZA966936B (en) | Process for the treatment of water. | |
ZA966815B (en) | Method of treating water. | |
AU5715296A (en) | Method of treating disorders associated with cholinergic hyp ofunctionality |